Business Wire

Murata Develops the World’s Smallest Class 006003-inch Size (0.16 mm x 0.08 mm) Chip Inductor

Share

Murata Manufacturing Co., Ltd. (TOKYO:6981) (ISIN:JP3914400001) announces the development of the world’s smallest class 006003-inch size (0.16 mm x 0.08 mm) chip inductor, which will be unveiled during CES 2025, January 7-10, Las Vegas, USA (Murata Booth: Las Vegas Convention Center, West Hall Booth #6500). This achievement represents a volume reduction of approximately 75% compared to the smallest 008004-inch size (0.25 mm × 0.125 mm) product.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250106014935/en/

Murata Manufacturing Co., Ltd.: World’s Smallest Class 006003 Size (0.16 mm x 0.08 mm) Chip Inductor (Photo: Business Wire)

The relentless pursuit of enhanced functionality and miniaturization in electronic mobile devices has led to a critical need for smaller, more efficient components. As a result, engineers are having to squeeze more components onto less board space. The use of chip inductors, essential components used in a wide array of these electronic devices, has also increased, with some of the latest smartphones incorporating hundreds of them. This trend has intensified the demand for further miniaturization of chip inductors to facilitate high-density mounting where space is at a premium.

To address this demand, Murata has consistently led efforts to reduce chip sizes by integrating its proprietary core technologies. “Following our success in introducing the world’s smallest multilayer ceramic capacitor (MLCC) in September 2024, our engineering teams are now developing a pioneering 006003-inch size chip inductor to further meet market demands,” says Takaomi Toi, General Manager of Inductor Product Development Dept. at Murata Manufacturing Co Ltd. “With the creation of the world’s smallest class prototype, we’re confident that this product represents an exciting addition to Murata’s extensive portfolio of market-leading chip inductors. This development continues to demonstrate Murata’s commitment to innovation and also marks a significant milestone in our quest to support the miniaturization and enhanced functionality of future electronic devices."

For more information or inquiries about this product, please contact us here.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250106014935/en/

Contacts

For more information, please contact:
Murata Manufacturing Co., Ltd.
Chae Hee PARK,
prsec_mmc@murata.com
Corporate Communications Department

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Logo Established for the “Japan Creator Support Fund” to Support the Global Success of Japan’s Next-Generation Creators and Artists30.6.2025 09:00:00 EEST | Press release

The Japan Arts Council (President: Mariko Hasegawa), with funding from the Agency for Cultural Affairs, has established the Japan Creator Support Fund to support projects nurturing Japan’s diverse creators and artists, and to support cultural facilities’ function enhancement. We are pleased to announce that the logo for the Fund has been established and that the English-language global website, which is promoting this project overseas, has been officially launched on Monday, June 30, 2025. A promotional video for international audiences is also now available on the website. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250627404244/en/ From the top left are the individual logos for the following support programs: the Creator & Artist Development Support Program [FOR CREATORS], the Support Program for Cultural Facilities Function Enhancement [FOR CULTURAL FACILITIES], the Creator Support Program (Program Development & Implem

From Waste to Strategic Metals: Circular Materials Achieves First Industrial-Scale Recoveries Under the Critical Raw Materials Act30.6.2025 09:00:00 EEST | Press release

Circular Materials announces two major milestones under the Critical Raw Materials Act: the recovery from industrial wastewater of the first kilogram of ruthenium and the first ton of nickel, preventing the release of heavy metals into the environment. These results were secured through strong collaborations with two leading companies in surface treatments: LEM, core company of the LEM INDUSTRIES Group, specialized in the luxury sector, and Argos Surface Technologies Group, a leader in industrial coatings. This success comes just a few months after the European Commission recognized Recover-IT as a strategic project, confirming the pivotal role of Circular Materials in securing critical raw material supplies, increasing recycling, and reducing the EU’s dependence on imports. Ruthenium and Nickel: crucial metals for a sustainable future Ruthenium, a noble metal from the platinum group, is essential for cutting-edge sectors such as advanced electronics, green hydrogen production, fine ch

SBC Medical added to membership of Russell 3000 ® Index28.6.2025 02:30:00 EEST | Press release

SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical”), a global franchise and provider of services for aesthetic clinics, has been added as a member of the broad-market Russell 3000® Index, effective after the US market opens on June 30, as part of the 2025 Russell indexes reconstitution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250608244276/en/ Yoshiyuki Aikawa-Director (Chairman), CEO Membership in the Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000®Index as well as the appropriate growth and value style indexes. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. According to the data as of the end of June 2024, about $10.6 trillion in assets are benchmarked against the Russell US indexes, which belong to

Altimetrik and SLK Software Join Forces to Create an AI-First Engineering Services Powerhouse27.6.2025 23:44:00 EEST | Press release

Altimetrik, a pure-play AI, Data and Digital engineering solutions company, today announced the signing of a definitive agreement to acquire SLK Software (“SLK”), a global technology services firm focused on delivering AI, intelligence automation and analytics solutions. The acquisition will further strengthen Altimetrik’s end-to-end enablement services and expand its customer reach, with a clear path to accelerate towards Altimetrik’s goal of reaching $1billion in annual revenue. The transaction remains subject to customary closing conditions and is expected to close in the second half of 2025. Financial details were not disclosed. Founded in 2000, SLK is recognized as a leader in the tech industry, and for its commitment to create innovative digital solutions. This strategic acquisition will significantly enhance the scale of Altimetrik’s capabilities, bringing together Altimetrik’s AI-first, platform-native engineering model and SLK’s full technology services stack that will further

PRD Therapeutics Announces Initiation of First-in-Human Study for PRD00127.6.2025 17:00:00 EEST | Press release

PRD Therapeutics, Inc., a clinical stage company focused on the development of novel lipid metabolism regulators targeting homozygous familial hypercholesterolemia (HoFH) and metabolic dysfunction associated fatty liver disease (MASH/MASLD), today announced that the company recently initiated dosing in a First-in-Human (FIH) clinical trial of PRD001, a first-in-class SOAT2 (formerly known as ACAT2) selective inhibitor. “We are excited to initiate dosing in this clinical trial of PRD001. Many clinical trials have been conducted on SOAT1/2 dual or SOAT1 selective inhibitors, but this is the first clinical trial of an SOAT2 selective inhibitor” said Kanji Hosoda, Ph.D., CEO and co-founder of PRD Therapeutics. “Several results with SOAT1 or 2 knockout mice have been published, suggesting that knocking out or inhibiting only SOAT2 is crucial to demonstrate safety and efficacy. PRD001 is the world's first and only SOAT2-selective inhibitor and is expected to exhibit safety and efficacy in hu

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye